



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kubo *et al.*

Appl. No. 09/665,510

Filed: September 19, 2000

For: **HLA Binding Peptides and Their  
Uses**

Confirmation No. 7164

Art Unit: 1644

Examiner: Schwadron, R.B.

Atty. Docket: 2060.005000D/HCC/PAC

**Fourth Supplemental Information Disclosure Statement under 37  
C.F.R. § 1.97(b)**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Fourth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Third Supplemental Information Disclosure Statement filed on April 30, 2003, in connection with the above-captioned application. A copy of each document is also provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

This Fourth Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Helene C. Carlson  
Agent for Applicants  
Registration No. 47,473

Date: 8/1/2003

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600



Page 1 of 1

FORM PTO-1449 <b>FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>		ATTY. DOCKET NO. 2060.005000D/HCC/PAC		APPLICATION NO. 09/665,510
		APPLICANT Kubo et al.		
		FILING DATE September 19, 2000		GROUP 1644

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						Yes No
AM						Yes No
AN						Yes No
AO2	EP 0 427 347 A1	05/15/1991	Europe			Yes No
AP						Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

AR				
AS	11	Cowan, E.P., et al., "Site-directed mutagenesis of an HLA-A3 gene identifies amino acid 152 as crucial for major histocompatibility complex-restricted and alloreactive cytotoxic T-lymphocyte recognition," Proc. Natl. Acad. Sci. USA 84:5014-5018, National Academy of Sciences (1987)		
AT	11	Sweetser, M.T., et al., "Class I Major Histocompatibility Complex-restricted T Lymphocyte Recognition of the Influenza Hemagglutinin. Overlap between Class I Cytotoxic T Lymphocytes and Antibody Sites," J. Exp. Med. 170:1357-1368, The Rockefeller University Press (1989)		

EXAMINER	DATE CONSIDERED

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.